[PEG IFN alpha-2a in the treatment of chronic hepatitis C in patients with treatment failure]

Abstract

Despite the significant advances that have been made in the treatment of chronic hepatitis C the efficacy of treatment response seems to be unsatisfactory. Treatment failure concern above one half of treated patients. It is estimated that the number of non-responders will be systematically increased. For these reasons as treatment strategies in these patients there is a need to define optimal way to use new therapies as: extending of treatment duration, higher initial doses of administered medications, an increase of patients adherence, changing of kind of pegylated interferon or treatment combinations PEG IFN + RBV with other drugs, especially HCV-enzymes inhibitors. In the work the data of efficacy of retherapy with PEG IFN alfa-2a+RBV administered during 72 weeks were present. Retreatment with PEG IFN alpha-2a and RBV in patients who fail to achieve SVR in the treatment with PEG IFN alpha-2b+RBV revealed high early viral response, in patients with advanced liver histology too. In the future there are planned treatment of chronic hepatitis C with combined therapy with IFN, specific HCV-enzymes inhibitors and antiviral medications.